t(14;18) and bcl-2 should not be used synonmously

In their review on challenging paradigms in lymphoma treatment, Bendandi et al. [1Go] used the term ‘bcl-2-positive cells’ when they were really talking about cells with translocation t(14;18).

I would like to encourage authors of scientific manuscripts to be strict in their terminology. Names of proteins are increasingly mixed up with genetic terms. In particular, the expression of bcl-2 is often used synonymously with translocation t(14;18) (q32;q21). Many cells transcribe bcl-2, a normal gene coding for the bcl-2 protein regulating apoptosis, not just cells with t(14;18). In fact, in the paper by Huang et al. [2Go], referenced by the authors, there was no difference in the expression of bcl-2 in the t(14;18)-positive and negative cases. The chromosomal translocation is the feature identifying the subset of diffuse large B-cell lymphoma with a germinal center gene expression profile, not the expression of the protein bcl-2.

N. Frickhofen*

Dr. Horst-Schmidt-Klinik, Department of Hematology and Oncology, Wiesbaden, Germany

* Email: norbert.frickhofen{at}hsk-wiesbaden.de

References

1. Bendandi M, Pileri SA, Zinzani PL. Challenging paradigms in lymphoma treatment. Ann Oncol 2004; 15: 703–711.[Free Full Text]

2. Huang JZ, Sanger WG, Greiner TC et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99: 2285–2290.





This Article
Full Text (PDF)
E-letters: Submit a response
Alert me when this article is cited
Alert me when E-letters are posted
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Disclaimer
Request Permissions
Google Scholar
Articles by Frickhofen, N.
PubMed
PubMed Citation
Articles by Frickhofen, N.